• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 26th September 2016

New Report Published: Improving Efficiency and Resource Allocation in Future Cancer Care

The Office of Health Economics (OHE) and the Swedish Institute for Health Economics (IHE) publish a report evaluating the efficiency of resource allocation in cancer care across Europe. Treatments for and diagnosis of cancer have experienced significant advancement over the…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Graph-1

The Office of Health Economics (OHE) and the Swedish Institute for Health Economics (IHE) publish a report evaluating the efficiency of resource allocation in cancer care across Europe.

Treatments for and diagnosis of cancer have experienced significant advancement over the past few decades. Yet the burden of cancer across an ageing European population continues to grow, whilst in parallel, healthcare systems are facing growing financial pressures.

OHE, in partnership with the Institute for Health Economics (IHE) in Sweden, have just published a report – initiated and funded by BMS – which evaluated the current burden of cancer and identified opportunities for increased efficiency in cancer care. The evidence focused specifically on the health and cancer care landscape in nine European countries (Belgium, Denmark, France, Germany, Italy, the Netherlands, Poland, Sweden, and the UK) as well as the EU27 average.

The report highlights that cancer represents a significant disease burden in Europe: 17% of the total disability-adjusted life years (DALYs) lost are due to cancer. Utilising secondary data, we evaluated country level cancer care spending, and how this relates to disease burden, measured in DALYs. 

Health care resources allocated to cancer vary substantially by country; Figure A shows that Germany spends significantly more on cancer relative to its burden compared with the European average, whereas Poland spends significantly less than the European average. Across tumour types, spending on lung cancer is significantly lower relative to burden than three other major cancers; with a ratio of spending to burden less than half that of ‘all cancer’ (see Figure B).

Figure A: Spend relative to disease burden compared with the European average for each tumour type (A negative number indicates a lower spend to burden ratio than the European average)

Figure B: Spend relative to disease burden (thousands Euros per DALY lost) by cancer type; EU27 average

The report acknowledges the importance of resource allocation decisions in the context of the availability of effective and cost-effective treatments in a disease area. However, it is nevertheless pertinent to note the proportionality between spending and burden. Compared with stroke and dementia, spend on cancer is lower relative to burden, only slightly higher than spend on ischemic heart disease (see Figure C).

Figure C: Spend relative to disease burden (thousand euros per DALY lost) by disease – average in EU27

Our analysis of the total economic burden to society looks beyond direct health care costs of cancer and assesses the magnitude of costs borne by cancer patients and society more generally. The direct costs of cancer to the health care system represent less than half of the total cost of cancer to society; ranging between 27% of total costs in Denmark to 42% in Italy.

Production losses from patients no longer being able to undertake paid work are significant, representing between a third and a half of total economic burden depending on the country. This is followed by informal care (the value of care provided by friends and family) and unpaid work (the value of unpaid work a cancer patient can no longer undertake such volunteering or being care givers themselves).

The report found that significant opportunity for improved efficiency exists in prevention activities and early diagnosis, for example targeting unhealthy behaviours such as high alcohol consumption and smoking, and the implementation of quality screening programmes particularly in breast, lung and colorectal cancer.

It is also possible to achieve greater efficiencies in the way we evaluate new treatments, and enhance their uptake. For example, reduced delays in regulatory approval and national-level access could be facilitated through managed entry agreements and the greater exploitation of real-world evidence. 

In addition, case study analyses revealed significant possible savings, such as the €7.1 billion that could be saved during the period 2016-2020, through increased generic and biosimilar competition in the oncology market.

Our report has identified several areas where efficiencies – or the way we allocate resources – can be improved. Some of these have the potential to be cost-saving. Other practices may also improve overall efficiency by improving patient outcomes, even if they require additional expenditure. The major challenge for society is to get the balance right: between outcomes for patients, spending and efficiency. 

View the short executive summary here.

Download the full report and data compendium here.

  • Health Data and Statistics
  • Economics of Innovation
  • Consulting Reports

Related News

Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
  • News
  • August 2020

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!